Expanded Access Policy

Expanded Access Policy

Plus Therapeutics is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. Our mission is to discover, develop, and deliver complex and innovative treatments for patients battling rare cancers.

Plus Therapeutics plans to develop, manufacture, and commercialize nanoliposome-encapsulated BMEDA-chelated radioisotope drugs to treat various types of cancer. Our initial focus is on developing BMEDA-chelated Rhenium NanoLiposome (RNL™). RNL is in the early stage of clinical development, being evaluated for the treatment of recurrent glioblastoma – a rare, incurable, and fatal disease.

Consistent with PLUS Therapeutics mission to bring innovative medicines to patients with serious or life-threatening illnesses or conditions, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible. We are privileged to collaborate with clinical investigators and with patients who participate in our studies to develop new, safe and effective therapies. As such, we believe participation in our clinical trial is the most appropriate way to access RNL at this stage of development. Information about our clinical trials, including eligibility criteria and locations, is available at www.clinicaltrials.gov.

Plus Therapeutics understands the interest of patients in accessing RNL outside of clinical trials and prior to regulatory approval for potentially life-threatening diseases, however we do not currently offer any Expanded Access programs for RNL.

Plus Therapeutics also recognizes the need for Expanded Access programs and will re-evaluate the status of our policy based on data from ongoing and future clinical trials.